B. Riley Securities Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $4-Report Released on 19th December 2023
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani has maintained a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) but has reduced the price target from $8 to $4. The report was released on December 19, 2023.
December 20, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B. Riley Securities reaffirms a Buy rating on Checkpoint Therapeutics but slashes the price target by 50% from $8 to $4.
The reduction in the price target by B. Riley Securities could lead to a negative perception among investors, potentially causing a short-term decline in CKPT's stock price. The Buy rating may mitigate some negative impact, but the significant cut in the price target is likely to be the dominant factor in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100